M

Magle Chemoswed Holding AB
STO:MAGLE

Watchlist Manager
Magle Chemoswed Holding AB
STO:MAGLE
Watchlist
Price: 32.6 SEK -4.12% Market Closed
Market Cap: 599.9m SEK
Have any thoughts about
Magle Chemoswed Holding AB?
Write Note

Magle Chemoswed Holding AB
Capital Expenditures

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Magle Chemoswed Holding AB
Capital Expenditures Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Capital Expenditures CAGR 3Y CAGR 5Y CAGR 10Y
M
Magle Chemoswed Holding AB
STO:MAGLE
Capital Expenditures
-kr15.1m
CAGR 3-Years
-24%
CAGR 5-Years
6%
CAGR 10-Years
N/A
AddLife AB
STO:ALIF B
Capital Expenditures
-kr308m
CAGR 3-Years
-49%
CAGR 5-Years
-44%
CAGR 10-Years
N/A
BICO Group AB
STO:BICO
Capital Expenditures
-kr291.2m
CAGR 3-Years
-30%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Biotage AB
STO:BIOT
Capital Expenditures
-kr163m
CAGR 3-Years
-37%
CAGR 5-Years
-31%
CAGR 10-Years
-17%
G
Genovis AB
STO:GENO
Capital Expenditures
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
MedCap AB (publ)
STO:MCAP
Capital Expenditures
-kr57.8m
CAGR 3-Years
-22%
CAGR 5-Years
-50%
CAGR 10-Years
-21%
No Stocks Found

Magle Chemoswed Holding AB
Glance View

Market Cap
599.9m SEK
Industry
Life Sciences Tools & Services

Magle Chemoswed Holding AB engages in the provision of contract development and manufacturing services to the pharmaceutical and medical device industry. The company is headquartered in Malmo, Skane. The company went IPO on 2020-06-30. The firm's operations are mainly conducted through the subsidiaries Magle Chemoswed AB and Adroit Science AB. The business is focused on process development and manufacturing of Active Pharmaceutical Ingredients (API) as well as research, development and manufacturing of products in the areas of wound care and diagnostics with particular focus on products based on degradables starch microspheres. Magle Chemoswed also functions as a consultancy in material characterization and solid phase analysis with a main focus on pharmaceutical companies.

MAGLE Intrinsic Value
83.52 SEK
Undervaluation 61%
Intrinsic Value
Price
M

See Also

What is Magle Chemoswed Holding AB's Capital Expenditures?
Capital Expenditures
-15.1m SEK

Based on the financial report for Dec 31, 2023, Magle Chemoswed Holding AB's Capital Expenditures amounts to -15.1m SEK.

What is Magle Chemoswed Holding AB's Capital Expenditures growth rate?
Capital Expenditures CAGR 5Y
6%

Over the last year, the Capital Expenditures growth was 10%. The average annual Capital Expenditures growth rates for Magle Chemoswed Holding AB have been -24% over the past three years , 6% over the past five years .

Back to Top